1-(((5-Nitro-2-furanyl)methylen)-amino)-2,4-imidazolidindion Produkt Beschreibung

Nitrofurantoin Struktur
  • CAS-Nr.67-20-9
  • Bezeichnung:1-(((5-Nitro-2-furanyl)methylen)-amino)-2,4-imidazolidindion
  • Englisch Name:Nitrofurantoin
  • Synonyma:Nitrofurantoin;1-(((5-Nitro-2-furanyl)methylen)-amino)-2,4-imidazolidindion
  • CBNumber:CB7346080
  • Summenformel:C8H6N4O5
  • Molgewicht:238.16
  • MOL-Datei:67-20-9.mol
1-(((5-Nitro-2-furanyl)methylen)-amino)-2,4-imidazolidindion physikalisch-chemischer Eigenschaften
  • Schmelzpunkt: :268°C
  • Siedepunkt: :380.75°C (rough estimate)
  • Dichte :1.5824 (rough estimate)
  • Brechungsindex :1.6700 (estimate)
  • storage temp.  : 0-6°C
  • Löslichkeit :DMF: soluble50mg/mL
  • pka :7.2(at 25℃)
  • Aggregatzustand :crystalline
  • Farbe :yellow
  • Wasserlöslichkeit :<0.01 g/100 mL at 19 ºC
  • Sensitive  :Light Sensitive & Hygroscopic
  • maximale Wellenlänge (λmax) :358nm(MeOH)(lit.)
  • Merck  :14,6599
  • BRN  :893207
  • Stabilität: :Stability Stable, but light-sensitive. Combustible. Incompatible with strong oxidizing agents, strong alkalies, strong acids. Decomposes upon contact with most metals other than stainless steel and aluminium.
  • CAS Datenbank :67-20-9(CAS DataBase Reference)
  • NIST chemische Informationen :Hydantoin, n-(5-nitro-2-furfurylidene)-1-amino-(67-20-9)
  • EPA chemische Informationen :2,4-Imidazolidinedione, 1-[[(5-nitro-2-furanyl)methylene] amino]-(67-20-9)

Nitrofurantoin Chemische Eigenschaften,Einsatz,Produktion Methoden

  • R-Sätze Betriebsanweisung: R22:Gesundheitsschädlich beim Verschlucken.
    R42/43:Sensibilisierung durch Einatmen und Hautkontakt möglich.
  • S-Sätze Betriebsanweisung: S22:Staub nicht einatmen.
    S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.
    S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
  • Chemische Eigenschaften lemon yellow crystalline powder
  • Verwenden counterirritant
  • Verwenden A nitrofuran antibiotic with low resistance potential that is rapidly metabolized by mammals. Active against both Gram-positive and Gram-negative bacteria. Nitrofurantoin is also a prooxidant that is cytotoxic due to the generation of intracellular H2O2. Antibacterial.
  • Definition ChEBI: An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.
  • Trademarks Ivadantin (Procter & Gamble);Furan;Nitrofan.
  • Antimicrobial activity It is active against almost all the common urinary pathogens, except Proteus mirabilis. It is bactericidal.
    It antagonizes the activity of nalidixic acid and other quinolones in vitro, but this combination is unlikely to be used clinically.
  • Acquired resistance Surprisingly for an agent that has been used for so long, resistance remains uncommon. R-factor-mediated resistance has been reported, but this appears to be very unusual. The mechanism of resistance seems to be a decreased nitroreductase activity in the target organism.
    There is cross-resistance within the nitrofuran group, but none with antibiotics of other chemical classes.
  • Allgemeine Beschreibung Odorless lemon yellow crystals or fine yellow powder. Bitter taste.
  • Air & Water Reaktionen Insoluble in water.
  • Reaktivität anzeigen Nitrofurantoin is sensitive to light. Nitrofurantoin is incompatible with alkalis. Nitrofurantoin is also incompatible with strong oxidizers and strong acids. Nitrofurantoin decomposes on contact with metals other than stainless steel and aluminum.
  • Hazard Questionable carcinogen.
  • Brandgefahr Flash point data for Nitrofurantoin are not available; however, Nitrofurantoin is probably combustible.
  • Pharmazeutische Anwendungen A synthetic compound available only for oral administration. There are three formulations, differing in their crystalline nature: microcrystalline, macrocrystalline, and a delayedrelease preparation containing a combination of the two. The macrocrystalline form is said to be less liable to give rise to the most common adverse event, nausea. However, pharmacokinetic and clinical trial evidence for this assertion is not very strong.
    It is slightly soluble in water (c. 200 mg/L) but more so in dilute alkali. Solubility in ethanol is modest (500 mg/L), but the compound dissolves very well in dimethylformamide (80 g/L). If packaged in light-resistant containers and kept at room temperature, it is stable for more than 5 years. The yellow solution should be kept in the dark.
  • Pharmakokinetik Oral absorption:>95%
    Cmax 100 mg oral: <2 mg/L after 1–4 h
    Plasma half-life:0.5–1 h
    Volume of distribution: 0.6 L/kg
    Plasma protein binding: 60–70%
    It is absorbed mainly from the proximal small intestine and the plasma peak concentration may not be achieved for as long as 4 h. The recommendation to take the drug with food may be motivated by reducing the incidence of nausea rather than increasing bioavailability.
    Bioavailability varies widely between different brands and this may not be apparent from results of standard in-vitro pharmaceutical tests. Therefore, different brands should not be substituted unless therapeutic equivalence has been formally established.
    Serum levels are low, owing to extensive metabolism and the short plasma half-life. Tissue concentrations are too low for adequate treatment of systemic infection, including pyelonephritis. Negligible concentrations are found in breast milk and only a small amount crosses the placenta.
    Metabolism and excretion
    About 20% of the dose is excreted in microbiologically active form in the urine, sufficient to give inhibitory concentrations against urinary pathogens for up to 6 h. With reduced renal function (creatinine clearance <60 mL/min), urinary excretion falls, and virtually ceases when creatinine clearance is below 20 mL/min. This gives rise to the risk of accumulation in the blood and inadequate urine levels. With this proviso, it can be given to elderly patients. Infants over the age of 3 months may also be treated, but in the absence of a suitable suspension, and at the recommended dosage, a 6-month baby would need to be given one-tenth of a standard 50 mg tablet.
  • Clinical Use Acute dysuria and frequency
    Bacteriuria in pregnancy
    Prophylaxis of recurrent cystitis (reduced dosage)
  • Nebenwirkungen Nausea, which may be combined with anorexia or vomiting, or both, occurs in about 30% of patients taking the microcrystalline form, causing about 10% to stop treatment. The frequency of nausea is approximately halved with the macrocrystalline formulation. Nausea is due to a direct effect on the vomiting center; it occurs early in the course, and its incidence may be reduced by taking the medication with food or milk.
    Pulmonary, hepatic, neurological and hematological side effects have been reported, but are very uncommon. There are two kinds of pulmonary reaction. Acute reactions are the more common, starting within 5–10 days of the first dose, or within a few hours on re-challenge. Symptoms may resemble those found in asthma, tracheobronchitis or pneumonia, and usually resolve permanently within 2 days. There may be an eosinophilia. Subacute or chronic reactions, often referred to as pneumonitis, are of more gradual onset, and resolve only slowly when the drug is stopped. Prolonged dyspnea and cough may be accompanied by fibrosis.
    Hepatic reactions follow prolonged drug usage and usually manifest as chronic active hepatitis, sometimes with cirrhosis. The prognosis is good, but recovery may take months. Peripheral neuropathy has been reported mainly in patients with pre-existing impaired renal function. The prognosis depends upon the severity of the symptoms. Unlike hepatic and pulmonary effects, for which immunological phenomena seem to be responsible, neurological events have been attributed to a direct toxic effect of the drug, one of its metabolites or the superoxide generated in vivo.
    In common with other nitrofurans, nitrofurantoin may cause hemolysis in patients who lack glucose-6-phosphate dehydrogenase.
  • Sicherheitsprofil Poison by ingestion and intraperitoneal routes. Human systemic effects: peripheral motor nerve recording changes, ataxia, changes in urine composition, and hemolysis with or without anemia. Human reproductive effects by ingestion: spermatogenesis. An experimental teratogen. Other experimental reproductive effects. Questionable carcinogen with experimental neoplastigenic data. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
  • Veterinary Drugs and Treatments Considered a urinary tract antiseptic, nitrofurantoin is used primarily in small animals, but also occasionally in horses in the treatment of lower urinary tract infections caused by susceptible bacteria. It is not effective in treating renal cortical or perinephric abscesses or other systemic infections.
Nitrofurantoin Upstream-Materialien And Downstream Produkte
Downstream Produkte
1-(((5-Nitro-2-furanyl)methylen)-amino)-2,4-imidazolidindion Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
  • Firmenname:Henan DaKen Chemical CO.,LTD.
  • Telefon:+86-371-55531817
  • Fax:
  • E-Mail:info@dakenchem.com
  • Land:CHINA
  • Produktkatalog:21671
  • Edge Rate:58
  • Firmenname:Henan Tianfu Chemical Co.,Ltd.
  • Telefon:0371-55170693
  • Fax:0371-55170693
  • E-Mail:info@tianfuchem.com
  • Land:CHINA
  • Produktkatalog:20672
  • Edge Rate:55
  • Firmenname:Mainchem Co., Ltd.
  • Telefon:+86-0592-6210733
  • Fax:+86-0592-6210733
  • E-Mail:sales@mainchem.com
  • Land:CHINA
  • Produktkatalog:32447
  • Edge Rate:55
  • Firmenname:career henan chemical co
  • Telefon:+86-371-86658258
  • Fax:
  • E-Mail:sales@coreychem.com
  • Land:CHINA
  • Produktkatalog:30002
  • Edge Rate:58
  • Firmenname:Chemwill Asia Co.,Ltd.
  • Telefon:86-21-51086038
  • Fax:86-21-51861608
  • E-Mail:chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com
  • Land:CHINA
  • Produktkatalog:23980
  • Edge Rate:58
  • Firmenname:Haihang Industry Co.,Ltd
  • Telefon:86-531-88032799
  • Fax:+86 531 8582 1093
  • E-Mail:export@haihangchem.com
  • Land:CHINA
  • Produktkatalog:8921
  • Edge Rate:58
  • Firmenname:Xiamen AmoyChem Co., Ltd
  • Telefon:+86 592-605 1114
  • Fax:
  • E-Mail:sales@amoychem.com
  • Land:CHINA
  • Produktkatalog:6372
  • Edge Rate:58
  • Firmenname:BOC Sciences
  • Telefon:1-631-619-7922
  • Fax:1-631-614-7828
  • E-Mail:inquiry@bocsci.com
  • Land:United States
  • Produktkatalog:20115
  • Edge Rate:58
  • Firmenname:Chongqing Chemdad Co., Ltd
  • Telefon:+86-13650506873
  • Fax:
  • E-Mail:sales@chemdad.com
  • Land:CHINA
  • Produktkatalog:35440
  • Edge Rate:58
67-20-9, Nitrofurantoin Verwandte Suche:
  • 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione
  • 1-[(5-nitrofurfurylidene)amino]hydantoin
  • LABOTEST-BB LT00134625
  • Furadonin
  • Furadonine
  • Furadontin
  • Furalan
  • Furaloid
  • Furantoin
  • Furatoin
  • Furina
  • 1-{[(5-nitro-2-furyl)methylene]amino}-2,4-imidazolidinedione
  • Nitrofurantoin,98%
  • nitrofurantonie
  • 1[N-(5-Nitrofur-2-yl)methyleneamino]-imidazolidine-2,4-dione
  • Furadoxyl, N-(5-Nitro-2-furfurylidene)-1-aminohydantoin, Nitrofurantoine
  • 1-[(5-Mitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
  • Danafur
  • Nitrofurantoin,Furadoxyl, N-(5-Nitro-2-furfurylidene)-1-aminohydantoin, Nitrofurantoine
  • Nitrofurantoin (500 mg)
  • 1-(((5-Nitrofuran-2-yl)Methylene)aMino)iMidazolidine-2,4-dione
  • Nitrofurantoi
  • Nitrofurantoin solution, 100ug/ml
  • Furantoin-13C,15N3
  • Furobactina
  • Fur-ren
  • Hydantoin, 1-[(5-nitrofurfurylidene)amino]-
  • Ituran
  • Macpac
  • macrobid
  • Macrodantin
  • N-(5-Nitro-2-furfurylideno)-1-aminohydantoina
  • N-(5-Nitrofurfurylidene)-1-aminohydantoin
  • NCI-C08902
  • NCI-C55196
  • Nierofu
  • Nifurantin
  • Nitoin
  • Nitrex
  • Nitrofuradantin
  • Novofuran
  • nsc2107
  • NSC-2107
  • N-Toin
  • Orafuran
  • Parfuran
  • Trantoin
  • Upiol
  • Urantoin
  • Urizept
  • Urodin